メインナビゲーションにスキップ 検索にスキップ メインコンテンツにスキップ

Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites

  • Masakatsu Nakamura
  • , Hisakazu Shiroeda
  • , Tomoki Fukuyama
  • , Tomiyasu Arisawa
  • , Jo Yonemura
  • , Tomoyuki Shibata
  • , Tomomitsu Tahara
  • , Daisuke Yoshioka
  • , Masaaki Ohkubo
  • , Akemi Kamatani
  • , Yuuko Katoh
  • , Ichiro Hirata

研究成果: ジャーナルへの寄稿 › 学術論文 › 査読

抄録

Background; Combined chemotherapy with S-1 and docetaxel was implemented in patient with advanced or recurrent gastric cancer associated with peritoneal dissemination and malignant ascites. Methods; S-1 was administered orally at 80 mg/m2 for 14 consecutive days and docetaxel was administered at 40 mg/m2 on day 1, followed by a 1-week rest, as one course, and the treatment was repeated until progression or severe toxicity. Results; Three out of the five patients showed response to the treatment. The three patients with response had diffuse-type tumor according to the Lauren's classification. The median number of treatment courses was 4. The median survival time was 315 days, the median time to treatment failure was 225 days, and the 1-year survival rate was 20%. Conclusions; These results suggest that combined therapy with S-1 and docetaxel is a promising treatment for advanced or recurrent gastric cancer with malignant ascites and peritoneal dissemination.

本文言語英語
ページ(範囲)7-10
ページ数4
ジャーナルAnnals of Cancer Research and Therapy
巻20
号1
DOI
出版ステータス出版済み - 2012

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

  1. SDG 3 - すべての人に健康と福祉を
    SDG 3 すべての人に健康と福祉を

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究
  • 薬理学(医学)

フィンガープリント

「Combination Chemotherapy with S-1 and Docetaxel in Advanced Gastric Cancer patient with Peritoneal Dissemination and Malignant Ascites」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル